Companies › Alimera Sciences
1 active drug program in 5 registered trials: 4 Phase 4, 1 Phase 3; Infectious disease, Ophthalmology; next expected readout Oct 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Fluocinolone Acetonide Glucocorticoid receptor agonist | NR3C1 | Phase 4 | Diabetic Macular Edema; Non-infectious Uveitis Affecting the Posterior Segment of the Eye; Diabetic Macular Edema (DME); Radiation Retinopathy | Oct 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04469595 | Fluocinolone Acetonide | Phase 4 | Diabetic Macular Edema | Ophthalmology | Dec 2024 |
| NCT07843849 | Fluocinolone Acetonide | Phase 4 | Diabetic Macular Edema (DME) | Ophthalmology | Mar 2028 |
| NCT06539481 | Fluocinolone Acetonide | Phase 4 | Non-infectious Uveitis Affecting the Posterior Segment of the Eye | Infectious disease | Oct 2028 |
| NCT05844982 | Fluocinolone Acetonide | Phase 3 | Radiation Retinopathy | Ophthalmology | Dec 2029 |
| NCT04910503 | Fluocinolone Acetonide | Phase 4 | Diabetic Macular Edema | Ophthalmology | Apr 2030 |
Laboratorios Sophia S.A de C.V. Santen SAS Oticara Australia Insud Pharma ReGenTree
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.